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1. Introduction   
As defined by the Infectious Diseases Society of America, encephalitis is “the presence of an 
inflammatory process of the brain associated with clinical evidence of neurologic 
dysfunction”(Tunkel et al., 2008). In the absence of appropriate data, it is difficult to estimate 
the worldwide incidence of encephalitis, but in Southeast Asia Japanese encephalitis virus 
infections alone causes some 30,000 to 50,000 cases of encephalitis annually (Misra & Kalita, 
2010; Tsai, 2000) and causes of encephalitis include, but are not limited to, bacterial, viral, 
fungal and parasite infections as well as autoimmune and post infectious encephalitis where 
the encephalitis follows a usually mild viral infection or vaccine immunization and results 
from an inappropriate immune response. More than one hundred different infectious agents 
have been known to cause encephalitis, and while bacteria such as Mycobacterium 
tuberculosis (TB) and Bartonella henselae (the agent that causes cat scratch disease) are 
significant causes of encephalitis, viral infections are responsible for the majority of cases of 
infectious encephalitis. Viruses that can cause encephalitis include rabies virus, herpes 
simplex virus, enteroviruses including polioviruses, coxsackieviruses, echoviruses and a 
number of arboviruses (arthropod-borne viruses).  
 
 
Table 1. Tick-borne flavivirus species 
There are over 500 known arboviruses, which predominantly belong to the Togaviridae, 
Bunyaviridae, Rhabdoviridae, Reoviridae and Flaviviridae families, and viruses that cause 
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encephalitis in humans belong to all of these families. Encephalitis causing Togaviridae 
belong to the Alphavirus genus and include Ross River, Chikungunya and Western-, Eastern- 
and Venezuelan equine encephalitis viruses, while encephalitis causing viruses in the family 
Bunyaviridae belong to the Nairovirus (Crimean-Congo hemorrhagic fever virus), Phlebovirus 
(Rift Valley fever virus) and Orthobunyavirus (La Crosse virus) genera. Chandipura virus 
(family Rhabdoviridae, genus Vesiculovirus) has been associated with encephalitis, although 
there remains little further information. The family reoviridae contains 12 genera 
(Orthoreovirus, Orbivirus, Rotavirus, Coltivirus, Aquareovirus, Cypovirus, Fijivirus, 
Phytoreovirus, Oryzavirus, Mycoreovirus, Seadornavirus and Idnoreovirus) at least two of which 
contain arboviruses associated with encephalitis, namely the genera Coltivirus (Colorado 
Tick fever virus) and Seadornavirus (Banna virus). The family Flaviviridae contains only three 
genera (Hepacivirus, Pestivirus and Flavivirus) but the Flavivirus genus contains some of the 
most widespread and important arboviruses as well as the most important and widespread 
viruses associated with encephalitis. 
 
 
Table 2. Mosquito-borne flavivirus species 
A total of 53 species of flaviviruses are listed in the latest version of the International 
Committee on Taxonomy of Viruses Master species list version 9 (ICTV, 2011). A further 23 
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viruses are considered to be strains belonging to the 53 species, while another two viruses 
(Cell fusing agent virus and Tamana bat virus) are considered tentative species in the genus 
(ICTV, 2011). The genus Flavivirus is divided into three clusters, the mosquito-borne cluster, 
the tick-borne cluster and the “no known arthropod vector” cluster. All flaviviruses of 
human importance belong to the mosquito-borne or tick-borne clusters. While flaviviruses 
that cause human disease are found in the “no known arthropod vector” cluster, these have 
not yet been responsible for significant outbreaks of human disease. Classification of 
flaviviruses was originally based upon classical studies using cross-neutralization tests, with 
viruses that induce cross reacting antibodies being placed into the same “serogroup”. In 
recent times however grouping of flaviviruses has been predominantly based upon genetic 
analysis with viruses being placed into groups based upon sequence analysis. For the 
majority of flaviviruses, these groupings are synonymous, although some differences do 
occur. For example the Cacipacoré virus which was originally considered an ungrouped 
flavivirus based on cross neutralization tests is now considered part of the Japanese 
encephalitis group based upon sequence data and phylogenic analysis.  
The tick-borne cluster of flavivirus is commonly divided into the mammalian tick-borne 
virus group and the seabird tick-borne virus group (see Table 1), while the mosquito -borne 
flaviviruses are commonly segregated into 7 groups (See Table 2). The no known arthropod 
vector group currently consists of 12 virus species, divided into 3 groups (See Table 3). 
 
 
Table 3. No known arthropod vector flavivirus species 
As with all arboviruses, arboviral flaviviruses are maintained in natural cycles in which they 
multiply in a blood sucking arthropod such as a mosquito or tick and are then transmitted 
to a vertebrate host via the saliva when the insect takes a blood meal. Replication of the 
virus in the vertebrate host causes viremia of a sufficient level to allow infection of a naïve 
mosquito as it feeds. When infected, the arthropod becomes infected for life while in 
contrast the vertebrate host normally undergoes an acute but normally self limiting 
infection. In natural transmission cycles neither the arthropod vector nor the vertebrate 
suffer significant consequences of the infection. With the exception of urban cycles of yellow 
fever and dengue fever viruses, humans are not the principal amplifying host and infection 
in humans occurs when the vector feeds on humans as an alternate to its normal vertebrate 
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host. In these cases infection is normally a dead end for virus transmission as the disease is 
usually of a low titer viremia, although the consequences may be significant for the human 
host. The “no known arthropod vector group” of flaviviruses remains poorly understood. 
They are predominantly associated with either rodents or bats, and the ecology of their 
transmission remains largely undefined. There are scattered reports of possible infections of 
humans, usually by direct infection, although there is little confirmatory evidence linking 
the pathogen with the disease. These viruses are however of significant interest given their 
potential for emerging into the human population.  
2. The encephalitic flaviviruses 
2.1 Epidemiology 
2.1.1 The Japanese encephalitis group. 
The Japanese encephalitis group of the mosquito-borne flavivirus cluster consists of 8 virus 
species (Table 2) of which 4 viruses (Japanese encephalitis virus, Murray Valley encephalitis 
virus, St. Louis encephalitis virus and West Nile virus) have been consistently associated 
with encephalitis in cases of human infection.    
2.1.1.1 Japanese encephalitis virus 
Japanese encephalitis is one of the most important encephalitic diseases worldwide, 
resulting in some 35,000 to 50,000 deaths annually (Misra & Kalita, 2010; Tsai, 2000). 
Humans can become infected as a consequence of the bite of an infected mosquito, although 
evidence suggests that humans are not a natural host, but rather a dead-end host for 
Japanese encephalitis virus infection (Rosen, 1986). Naturally Japanese encephalitis virus is 
transmitted in an enzootic cycle among birds, particularly ardeid wading birds, and 
mosquitoes, principally Culex tritaeniorhynchus (Halstead & Jacobson, 2003) and Culex 
quinquefasciatus. The geographic distribution of Japanese encephalitis virus is mainly in the 
Asian region including India, China, and all of South-East Asia, although outbreaks have 
also been reported in Australia. Pigs have become an important host for maintaining, 
amplifying and spreading Japanese encephalitis virus as they undergo a long lasting 
viremia upon infection and are a preferred feeding source for Culex tritaeniorhynchus. The 
commercial pig farm industry both provides a source of susceptible animals in endemic 
areas, as well as potentially spreading the disease through the transport of infected animals. 
In Southeast Asian countries Japanese encephalitis virus is the leading reported cause of 
acute encephalitis in children, accounting for approximately 40% of cases (Solomon et al., 
2002; Srey et al., 2002). 
2.1.1.2 Murray Valley encephalitis virus 
Murray Valley encephalitis virus (sometimes called Australian encephalitis) is spread 
primarily by Culex annulirostris, and is believed to be endemic only in Australia and Papua 
New Guinea. Since the last major outbreak in Australia in 1974, which infected nearly 60 
patients, only sporadic outbreaks have been recorded. 
2.1.1.3 St. Louis encephalitis virus 
St. Louis encephalitis virus is distributed over much of the Americas, and is found in 
Canada (Ontario), the United States (especially in western states and in the southeast), 
Trinidad, Jamaica, Panama, Brazil, and Argentina. In North America approximately 25-50 
individuals are symptomatically infected each year and significant outbreaks affecting up to 
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800 people per 100,000 occur every 5 to 15 years in the Americas. The last major epidemic 
recorded was in 1990 in Florida which resulted in 11 deaths. Passeriforme and 
Columbiforme birds are believed to be the major reservoir species, and transmission is by 
Culex spp mosquitoes.   
2.1.1.4  West Nile virus 
West Nile virus is the most wide spread flavivirus with a worldwide distribution including 
Africa, Asia, Europe, and North America (Bakonyi et al., 2005). West Nile virus is naturally 
maintained in a cycle between bird feeding mosquitoes and wild animals, mainly birds. The 
natural cycle primarily involves the Culex species of mosquitoes in particular Culex pipiens, 
Culex quinquefasciatus and Culex restuans which are the most important West Nile virus 
vectors. A broad range of mammalian species are found to be susceptible to natural 
infection with West Nile virus following infectious mosquito bite(s) and includes humans, 
horses, cats, rabbits, skunks, squirrels, chipmunks, and two species of bats (Marfin et al., 
2001). Although initially West Nile virus was considered to have a minor human health 
impact, West Nile virus epidemics have become widely distributed causing several 
hundreds of reported cases in Romania in 1996 (Tsai et al., 1998), Russia in 1999 (Platonov et 
al., 2001), and Israel in 2000 (Chowers et al., 2001). West Nile virus has also been a 
significant cause of human illness in the United States. By the end of 2002, West Nile virus 
activity had been identified in 44 states and the District of Columbia resulting in reports of 
over 4,000 human cases of West Nile disease (including several thousand cases of 
meningoencephalitis cases and almost 300 deaths). Reported deaths were also recorded for 
wild animals including 16,741 dead birds and 14,571 equine cases (Centers for Disease 
Control and Prevention (CDC), 2003). Phylogenetic analyses have shown 2 distinct lineages 
of West Nile virus strains which were isolated in different geographic regions: I and II 
(Berthet et al., 1997; Lanciotti et al., 1999; Savage et al., 1999). Lineage I has a wide 
distribution including Africa, Asia, Europe, and North America and is associated with all 
the outbreaks of human and equine diseases. Lineage II is restricted to endemic enzootic 
infections in Africa and has not been associated with human encephalitis (Berthet et al., 1997).  
2.1.2 The tick-borne encephalitis group 
The tick-borne encephalitis group consists of two main subgroups (the mammalian tick-
borne virus group and the seabird tick-borne virus group), with human pathogens being 
limited to the mammalian tick-borne group (Table 1). Three virus species within this group 
have a consistent association with encephalitis, namely Louping ill virus, Powassan virus 
and Tick-borne encephalitis virus. The position of the Kadam virus within the seabird tick-
borne cluster remains somewhat controversial, but this virus has not been associated with 
significant levels of human infection nor encephalitis, and as such is not discussed further in 
this article. Similarly Langat virus is naturally attenuated and does not seem to be associated 
with human disease under natural conditions. While there are reports of Langat associated 
encephalitis in humans, these have occurred solely in large scale vaccination trials 
attempting to use Langat virus to protect against Tick-borne encephalitis virus infection in 
Russia.  
2.1.2.1 Louping ill virus 
Louping ill virus occurs mainly in the British Isles, where sheep are the most important 
reservoir host for this virus, but amplification can also occur in grouse and mountain hares 
which have been implicated as maintenance hosts via non-viremic transmission between co-
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feeding ticks. The principal vector for transmission is the tick Ixodes ricinus, although other 
species of tick including Rhipicephalus appendiculatus, Ixodes persulcatus and Haemaphysalis 
anatolicum are capable of transmitting the virus. Louping ill virus produces a symptomatic 
disease in sheep which may have a neurological component including encephalitis. Fewer 
than 100 cases of Louping ill infection of humans have been reported in the British Isles, 
most commonly in agricultural workers, although a number of cases of laboratory based 
infection have been reported. While direct tick transmission to humans is a possibility, there 
are few reliable reports of transmission by this route, and infection may arise predominantly 
through contact with sick animals or infected tissues or fluids.  
2.1.2.2 Powassan virus 
Only between 20 and 50 cases of human Powassan virus infection have been reported since 
the first identified case of a boy who died from infection with the virus in Powassan, 
Ontario in 1958. The virus is widely distributed in North America in both Canada and in the 
United States, and reports have identified Powassan virus in locations in southeastern 
Siberia. The virus is maintained in transmission cycles that include several species of small 
wild mammals including the woodchuck (Marmota monax), squirrels, chipmunks and deer 
mice and several species of Ixodes ticks. In eastern and central Canada, the transmission 
cycle between the woodchuck and the tick Ixodes cookei may be of particular importance.  
2.1.2.3 Tick-borne encephalitis virus 
Tick-borne encephalitis virus is one of the most important tick-borne flaviviruses causing a 
serious acute central nervous system infection and the distribution of this disease stretches 
from seven countries in northern Asia to central Asia and 25 Western European countries 
(Charrel et al., 2004). Naturally, Tick-borne encephalitis virus is maintained in a cycle 
involving ticks and wild vertebrate hosts. While several different species of tick have been 
found to be biologically competent to transmit Tick-borne encephalitis virus in the 
laboratory, in nature, because of specific ecological limiting factors, only Ixodes ricinus in 
Europe, and Ixodes persulcatus and Haemaphysalis concinna in Russia, appear to play a 
significant role in the virus maintenance (Labuda & Randolph, 1999). There are three 
subtypes of Tick-borne encephalitis virus, the European (also known as Central European 
encephalitis virus), Siberian (also known as west-Siberian encephalitis virus) and Far-
eastern (also known as Russian Spring/Summer encephalitis virus), in which the degrees of 
virulence are different (Mansfield et al., 2009). Transmission of Tick-borne encephalitis virus 
through raw milk or cheese from goats, sheep and cows was previously responsible for 10 to 
20% of cases of Tick-borne encephalitis virus transmission in central Europe.  
2.2 Pathogenesis and clinical features 
All of the encephalitic flaviviruses have several features in common and they all raise a 
significant immune response. The initial response is generally a non-specific innate response 
that occurs within the first few days after infection, and pathogen specific humoral 
(antibody) and cell mediated immunity begin four to seven days after infection. The 
antibody response raised is frequently extremely broad and cross reactive with other 
flaviviruses and generates lifelong immunity towards the homotypic virus as well as 
potentially partial protection against other flaviviruses. With each of the encephalitic 
flaviviruses, symptomatic infections are greatly outnumbered by asymptomatic infections, 
and symptomatic infections generally generate a broad spectrum of responses in patients 
ranging from a mild disease typically characterized by fever and headache to severe 
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encephalitis or meningitis leading often to coma and death. The broad range of responses to 
the infecting pathogen suggests a complex interplay between host and viral factors that 
remains largely unexplained. Where encephalitis is a component of the disease pathology, 
long term neurological deficit is common. The underlying mechanism by which some 
flaviviruses, but not others, cause encephalitis is still the subject of considerable 
investigation. Where flavivirus infection does lead to encephalitis, the mechanism by which 
the virus crosses the blood brain barrier remains to be fully elucidated, and several 
mechanisms have been proposed. Studies of neurotropism in a hamster model of St. Louis 
encephalitis virus infection have shown the importance of axonal transport through 
olfactory neurons (Monath et al., 1983), thus evading the blood brain barrier. However, 
postmortem studies on patients who died from Japanese encephalitis virus infection showed 
diffuse infection throughout the brain, indicating a hematogenous route of entry (Desai et 
al., 1995; Johnson et al., 1985). Infection of parenchyma may therefore result from either 
simple diffusion from vascular endothelial cells at sites where the integrity of the blood 
brain barrier has been compromised due to trauma, or through replication of the virus in the 
endothelial cells of brain capillaries, and release of the virus into the brain. Alternatively, 
some evidence has suggested a role for overproduction of inflammatory cytokines as a 
consequence of activation of the Toll-like receptor (TLR) 3 as causative in weakening the 
blood brain barrier in West Nile virus infections (Wang et al., 2004). However, a simple 
increase in permeability of the blood brain barrier seems not to be the primary determinant 
of lethality in animal model systems (Morrey et al., 2008), suggesting that additional factors 
need to be elucidated. Whether all encephalitic flaviviruses use the same mechanism, or 
indeed whether a specific virus utilizes several pathways remains to be determined.  
2.2.1 The Japanese encephalitis virus group 
2.2.1.1 Japanese encephalitis virus 
Population based studies in areas with endemic Japanese encephalitis have estimated the ratio 
of overt: inapparent Japanese encephalitis virus infections as approximately 1:250 (Gajanana et 
al., 1995). Where symptomatic infection occurs, symptoms start some five to 15 days after 
infection. Mild infections are generally characterized by a fever and headaches while more 
severe disease is characterized by nausea and vomiting, neck stiffness, stupor, disorientation, 
convulsions and paralysis. While a proportion of patients make a rapid and spontaneous 
recovery, up to 30% of patients admitted to hospital with Japanese encephalitis die. For non-
fatal cases of Japanese encephalitis, approximately 50% of the survivors suffer from severe 
neurological sequelae, and even those who have been classed as having “good recovery” have 
evidence of neurological damage (Kumar et al., 1993; Solomon et al., 2000). There is some 
evidence that Japanese encephalitis virus may establish a latent infection in some patients that 
can lead to recurrence of symptoms many months later (Sharma et al., 1991).  
2.2.1.2 Murray Valley encephalitis virus 
Serological surveys suggest that only 1 in 1000 infections with Murray Valley Encephalitis 
virus result in a symptomatic disease. Where a symptomatic infection does occur, symptoms 
arise some one to four weeks after exposure to the virus and may include headache, nausea, 
vomiting, myalgia and a rash. In a proportion of symptomatic cases lethargy, confusion, 
convulsions and fits may occur indicative of neurological involvement and coma and death 
may follow. Up to 25% of cases of symptomatic Murray Valley encephalitis infection are 
fatal, and survivors may show long term neurological deficits. 
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2.2.1.3 St. Louis encephalitis virus 
As with other flavivirus infections, infections with St. Louis encephalitis virus are generally 
asymptomatic, with an inapparent: apparent infection ratios of between 16:1 and 425:1. The 
incubation period between infection and the onset of symptoms is believed to be 21 days, 
and symptomatic infection usually results in a mild disease characterized by headache, 
tiredness and dizziness, sometimes with nausea and vomiting. Severe disease with 
neurologic involvement including encephalitis or aseptic meningitis is rare, and more 
commonly found in older adults. Long term disability and death can occur, and the disease 
is fatal in up to 10% of patients. 
2.2.1.4 West Nile virus 
Most infections with West Nile virus are asymptomatic and symptomatic West Nile fever 
occurs in only 20-30% of cases of infection. West Nile fever is a flu-like illness which 
develops 3 – 14 days post infection and is characterized by fever, headache, back pain, 
fatigue, arthralgia and myalgia (Hayes et al., 2005) with symptoms sometimes persisting for 
several weeks. A maculopapular rash occurs in about 50% of cases. Neurological 
involvement occurs in less than 1% of infections, and is characterized by encephalitis in 60% 
of cases, and meningitis in 40% of cases. Neurological involvement can result in long term 
cognitive and neurological deficits.  
2.2.2 The tick-borne encephalitis group 
2.2.2.1 Louping ill virus 
Given the small number of cases of Louping ill virus infection recorded, accurate clinical 
data is somewhat scarce. A four to seven day incubation period is believed to occur after 
infection before the onset of symptoms. Evidence suggests that the disease evinces with a 
mild fever, headache and tiredness which may be mistaken for flu, and serological studies in 
abattoir workers suggest a greater degree of exposure to the virus than symptomatic cases 
would suggest. In some infections the mild symptoms maybe the only pathological 
expression of the disease, however,  in other infections after an apparent remission period of 
approximately one week, the fever recurs together with neurologic complications which can 
include meningoencephalitis or paralytic poliomyelitis. Even with the severe form of 
Louping ill virus infection, death is rare, and although convalescence maybe prolonged, 
there are no apparent long term neurological deficits. 
2.2.2.2 Powassan virus 
While an extremely limited number of cases of infection with Powassan virus have been 
recorded, serological evidence suggests that large numbers of people have been exposed to 
the virus. Serological surveys in Ontario between 1959 and 1961 suggested an average 
yearly exposure of approximately 2% of the population, suggesting that symptomatic 
infections with Powassan virus are significantly outnumbered by asymptomatic infections.  
Where symptomatic infection occurs, an estimated 8 to 34 days after infection, early 
symptoms include headache, lethargy and disorientation, while in the later progression of 
the disease, encephalopathy is extremely common. The case fatality rate for Powassan virus 
infection is believed to be 10 to 15%, but severe, long term neurological sequelae are present 
in up to 50% of the survivors (Ebel, 2010; Gholam et al., 1999).  
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2.2.2.3 Tick-borne encephalitis virus 
An estimated 90% of cases of infection with Tick-borne encephalitis virus are believed to be 
asymptomatic or to result in a non-specific illness. Symptomatic disease, which may last 
from two to four days is characterized by a non-specific flu like disease with fever, 
headache, myalgia and vomiting and occurs after an incubation period of one to two weeks, 
although the range of onset of symptoms extends between two days and one month. 
Reports suggest infection through raw milk and milk products may lead to a faster onset of 
symptoms. In approximately one third of cases the disease presents as a biphasic disease 
and after an approximately one week (range 1 to 20 days) asymptomatic period the second 
phase of the disease occurs. The second phase of the disease is heralded by the onset of a 
high fever coupled with central nervous system involvement and involves symptoms of 
meningitis (fever, headache, stiff neck) or encephalitis (drowsiness, confusion, sensory 
disturbances, paralysis) or meningoencephalitis. Encephalitis is more commonly found in 
adults over the age of 40, while children are more likely to experience meningitis. Infection 
with Tick-borne encephalitis virus may result in mortality or long-term neurological 
sequelae in 35–58% of patients. The fatality rate associated with clinical infection is 0.5–20% 
(World Health Organization, 2006), although the Far Eastern subtype is generally associated 
with a higher mortality rate (5 to 20% fatality rate) than the European subtype (1 -2%). As 
with Japanese encephalitis virus, some data suggests that the Tick-borne encephalitis virus 
may be able to establish latent infections leading to the recurrence of symptoms after a long 
remission period (Ogawa et al., 1973). 
2.3 Flavivirus life cycle  
Flaviviruses are spherical viruses some 40-60nm in diameter consisting of three structural 
proteins, Envelope (E), Membrane (M) and Capsid (C) and a single stranded (+) sense RNA 
molecule of approximately 11kb. The RNA contains both 5’ and 3’ untranslated regions and 
is usually not polyadenylated (although some strains of tick-borne encephalitis may contain 
a poly(A) tract) and encodes the three structural proteins (C, E and pre-M), as well as seven 
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) and is translated as 
a single open reading frame and processed by host and virally encoded proteases  (Henchal 
& Putnak, 1990; Perera & Kuhn, 2008). The viruses contain a significant amount of lipid (15-
20% by weight) that is similar in content to the host cell membranes (Russell et al., 1980). 
Flaviviruses predominantly enter into both insect and mammalian cells through endocytosis 
into clathrin coated pits following binding to a specific receptor or receptors. While clathrin 
mediated endocytosis has been clearly established for a number of different flaviviruses 
through studies using biochemical and genetic characterization methods in a wide range of 
cell types, characterization of the receptor or receptor complexes used in the initial binding 
remains much more poorly characterized, and evidence suggests that virus entry may be 
cell type specific. However, it is clear that it is an interaction between the flavivirus envelope 
(E) glycoprotein that mediates the interaction of the virus with the host cell and the 
flavivirus E glycoprotein is believed to contain the components responsible for several 
important viral functions including target cells binding, induction of protective immunity, 
mediation of membrane fusion and virus assembly (Chang, 1997; Heinz, 1990; Kimura & 
Ohyama, 1988; Klasse et al., 1998). The E protein is highly conserved amongst all 
flaviviruses and shares common features. Conservation of cysteine residues and similar 
hydrophobicity profiles suggest a common folded structure of the E protein for all 
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flaviviruses. Recently high resolution flavivirus E protein crystal structures of dengue virus 
serotype 2 (Modis et al., 2003) and tick-borne encephalitis (Rey et al., 1995) have shown their 
close relationship in overall dimeric structure, protein folding and a similar set of six 
disulfide bonds (Modis et al., 2003; Rey et al., 1995). The approximately 55 to 60kDa E 
protein contains 494 to 501 amino acids folded into three distinct structural and functional 
domains; domains I, II and III which correlate well with the previously defined antigenic 
domains C, A, and B. (Chang, 1997; Heinz et al., 1983; Roehrig et al., 1983). Domain I and III 
(C and B) contain predominately subcomplex- and type-specific epitopes, whereas domain 
II (A) the dimerization domain, contains broadly flavivirus-cross-reactive epitopes and also 
subtype-specific epitopes (Mandl et al., 1989). The flavivirus domain III has been shown to 
participate in virus attachment through its interaction with a cellular receptor (Chu et al., 
2005; Crill & Roehrig, 2001; Hung et al., 2004; Hurrelbrink & McMinn, 2001; Volk et al., 
2004). The participation of domain III in cell entry appears to involve the presence of a 
putative receptor binding loop (Modis et al., 2003) and a heparan sulphate binding site 
(Chen et al., 1997; Mandl et al., 1989; Twiddy et al., 2002; Wu et al., 2004) including the 
membrane fusion peptides (Allison et al., 2001). Apparently the flavivirus E glycoprotein is 
a crucial determinant of the host range, tissue tropism, and virulence of the virus (Crill & 
Chang, 2004; Mandl, 2005). After virus entry into the target cell, the acid environment of the 
endosome vesicle triggers conformational changes in the virions and fusion of viral and cell 
membranes and particle disassembly occur (Dimitrov, 2004; Marsh, 1984). 
The non-structural proteins then initiate the replication of the viral genome in close 
association with the ER, and the newly synthesized RNA is packaged by the C protein 
forming a nucleocapsid complex. The nucleocapsids bud from the ER and become 
enveloped by a lipid membrane carrying with it associated envelope (E) and the pre-
membrane (prM) proteins which have formed initially into prM/E heterodimers and 
subsequently these heterodimers associate into trimers (Kuhn et al., 2002; Perera & Kuhn, 
2008). The newly assembled particle is in an immature form, in which the prM/E 
heterodimers project from the surface as 60 trimeric spikes and has a diameter of 
approximately 600 Angstroms (Li et al., 2008; Yu et al., 2009). After budding from the ER, 
the immature viruses transit the secretory pathway, where the prM protein is cleaved by the 
cellular furin protease after a major conformational change induced by the acidic 
environment of the trans-Golgi network resulting in exposure of a furin cleavage site (Li et 
al., 2008; Yu et al., 2009). In the slightly acidic pH of the trans-Golgi network the cleaved 
“pr” domain of the prM protein remains in association with the essentially mature virus 
particle, preventing premature membrane fusion inside the cell. Exposure to a neutral pH 
upon virion exposure to the extracellular milieu induces dissociation of the “pr” peptide 
from the now mature virion (Yu et al., 2009).  
2.4 Current and future vaccine development 
The development of vaccines to protect against infections by members of the flavivirus 
genus has been extremely uneven. It is of note that the vaccine against the prototype 
flavivirus, Yellow fever virus, the causative agent of yellow fever, is one of the most 
successful live attenuated vaccines, with the currently used YF-17D derivatives capable of 
inducing a protective level of neutralizing antibodies in 99% of recipients within 30 days 
from a single dose (Monath, 2001). In contrast, the effort to develop an effective live 
attenuated vaccine or vaccines against dengue virus remain incomplete, despite more than 
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60 years of investigation since the pioneering studies of Sabin and Schlesinger (Sabin & 
Schlesinger, 1945). For the flaviviruses that are associated with encephalitis, the picture is 
somewhat more promising.  
2.4.1 Japanese encephalitis virus 
For the most significant flavivirus causing encephalitis, Japanese encephalitis virus, vaccines 
have been available since the 1950s. The original vaccine widely distributed in much of Asia 
was a formalin inactivated whole virus formulation grown in mouse brain using either the 
Nakayama or Beijing-1 strains (Halstead & Thomas, 2010). Despite acceptable protection 
levels after one, two or three vaccination doses and a significant decrease in the number of 
cases of Japanese encephalitis in countries where the vaccine was widely used (Solomon, 
2004; Solomon et al., 2000), possibly unfounded concerns as to adverse reactogenicity of this 
formulation (Halstead & Thomas, 2010) led to discontinuation of production of this vaccine. 
The mouse brain produced vaccine was developed in Japan and used in much of Asia for 
indigenous populations as well as used for vaccination of travelers to endemic areas. China 
however developed its own, cell culture produced, whole virus inactivated vaccine for 
Japanese encephalitis based on culture of the P-3 or Beijing-3 strain of Japanese encephalitis 
in primary hamster kidney (PHK) cells, which was later superseded by the production of a 
live attenuated vaccine, SA14-14-2. This vaccine has been reported to induce excellent, long 
lived protection after a single dose administration and is currently distributed in China and 
several other Asian countries. The SA14-14-2 vaccine strain was the starting point for 
development of a further, whole virus formalin inactivated vaccine IXARO (IC51) 
developed originally by the Walter Reed Army Institute of Research. This vaccine is 
produced in Vero (African green monkey kidney) cells and induces high levels of protection 
after two or three doses. It is expected that this vaccine will be widely distributed (Halstead 
& Thomas, 2010). One further Japanese encephalitis vaccine candidate is currently on the 
brink of being widely marketed and distributed. This vaccine, the so called IMOJEV (JE-CV 
and previously called ChimeriVax-JE) vaccine is a live attenuated recombinant vaccine 
based upon the exceedingly well characterized YF-17D backbone, with the prM and E 
coding sequences from Japanese encephalitis virus replacing the equivalent YF-17D 
sequences.   This vaccine offers levels of protection apparently equivalent or greater than 
other existing vaccines with a single dose administration generating protective antibody 
levels in 95% (children) or 99% (adults) of recipients by 1 month post-administration 
(Halstead & Thomas, 2010). Overall, with three effective and apparently safe vaccines either 
being distributed or in the process of being distributed, the outlook for control of Japanese 
encephalitis is promising. 
2.4.2 West Nile virus 
There is currently no licensed vaccine to protect against West Nile virus infection for use in 
humans although five vaccines are available for vaccination of horses. Two of these 
vaccines, the West Nile-Innovator™ (Fort Dodge Animal Health) and the Boehringer-
Ingelheim VeteraTM vaccine consist of whole inactivated virus. In both cases the vaccine is 
derived from an equine isolate of West Nile virus. The third vaccine available (Prevenile™, 
Intervet/Schering-Plough Animal Health) is a chimeric vaccine using the Yellow fever 
vaccine YF-17D backbone and the pre-membrane and envelope proteins of West Nile virus, 
although a recall notice is currently in effect on this vaccine due to reports of adverse 
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reactions (http://www.prevenile.com/PDF/PreveNile%20Letter.pdf; accessed 
17/02/2011). The fourth horse vaccine for West Nile virus (Recombitek™, Merial) is a 
recombinant canarypox vector containing the pre-membrane and envelope proteins of West 
Nile virus, while the fifth vaccine (West Nile- Innovator® DNA, Fort Dodge Animal Health) 
is a DNA vaccine encoding the West Nile virus prM and E proteins.  
Perhaps unsurprisingly, development of a human vaccine largely follows from the progress 
made with equine vaccines. A phase II trial of a chimeric YF-17D backbone with the West 
Nile pre-membrane and envelope proteins has been undertaken (Biedenbender et al., 2011). 
This vaccine largely follows the equine Prevenile vaccine strategy, but includes three 
mutations in the E protein predicted to reduce neurovirulence, and results from the Phase II 
study suggest that the construct is highly immunogenic and well tolerated (Biedenbender et 
al., 2011). Similarly, a Phase I trial of DNA vaccine encoding the pre-membrane and envelope 
proteins of the NY99 strain of West Nile virus was completed in 2007 (Martin et al., 2007).     
Other potential vaccine candidates include a live attenuated Schwarz strain of measles virus 
expressing the secreted form of E protein from a virulent strain of West Nile virus (Despres 
et al., 2005), a live attenuated WNV/Dengue 4 virus chimera (Pletnev et al., 2003),  RepliVax 
WN, a defective pseudoinfectious West Nile virus lacking a functional capsid gene (Mason 
et al., 2006; Widman et al., 2008; Yamshchikov et al., 2004), an attenuated West Nile 
prototype virus (Yamshchikov et al., 2004) and a plasmid DNA vaccine containing the 
infectious full-length RNA genome of Kunjin (KUN) virus (Hall et al., 2003), a subtype of 
West Nile virus. In addition subunit vaccines including a bacterially expressed domain III of 
West Nile virus E protein (Chu et al., 2007; Martina et al., 2008) and a  recombinant 
truncated E (trE) and NS1 protein construct  expressed in Drosophila S2 cells (Lieberman et 
al., 2007; Watts et al., 2007) are under investigation.  
As with Japanese encephalitis virus, the prospect for a human vaccine for West Nile virus 
infections is promising, with the leading candidates at various stages of clinical trials as well 
as a number of promising candidates still at the early developmental stage.   
2.4.3 Murray Valley encephalitis virus 
There is currently no vaccine to protect against infection with Murray Valley encephalitis, 
and given the limited distribution and low incidence of cases, it is possible that a specific 
commercial vaccine against Murray Valley encephalitis will not be developed. However, 
animal studies have suggested that immunization with a live chimeric anti-Japanese 
encephalitis vaccine (ChimeriVax-JE) may provide protection against the closely related 
Murray Valley encephalitis virus (Lobigs et al., 2009). However, preliminary animal based 
studies using Murray Valley encephalitis recombinant subviral particles (Kroeger & 
McMinn, 2002) or E and NS1 proteins expressed in a recombinant vaccinia virus (Hall et al., 
1996) have been undertaken which may possibly lead to the development of a specific 
Murray Valley encephalitis vaccine.  
2.4.4  St. Louis encephalitis virus 
There is currently no commercially licensed vaccine to protect against infection with St. 
Louis encephalitis virus. The development of possible vaccines follows closely the 
development of West Nile virus vaccines. Potential vaccine constructs evaluated at least in 
animal studies include chimeric yellow fever/ St. Louis encephalitis virus constructs 
consisting of the well characterized yellow fever vaccine strain YF-17D backbone with the 
pre-membrane and envelope coding sequences of a virulent (MSI-7) or an attenuated 
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(CorAn9124) strain of St. Louis encephalitis virus (Pugachev et al., 2004) and a chimeric 
dengue serotype 4/ St. Louis encephalitis virus construct consisting of the dengue serotype 
4 backbone and the pre-membrane and envelope coding sequences of Hubbard strain of St. 
Louis encephalitis virus (Blaney et al., 2008). In addition a prime/boost strategy using 
sequential immunization with a vaccinia virus expressing St. Louis encephalitis virus pre-
membrane and envelope proteins followed by purified recombinant envelope protein 
(Venugopal et al., 1995) and a DNA vaccine candidate based upon expression of the St. Louis 
encephalitis virus pre-membrane and envelope proteins under control of the cytomegalovirus 
immediate-early promoter have been investigated in mice (Phillpotts et al., 1996).  
2.4.5 Louping ill virus 
Probably as a reflection of the extremely low incidence of Louping ill virus infections in 
humans, little vaccine development has taken place, although  a vaccine for sheep has been 
in use in the United Kingdom since before 1935. The original vaccine was prepared from 
formalin inactivated virus grown in sheep brains, but this practice was halted when causal 
evidence of a link with spread of the sheep prion disease Scrapie was uncovered (Nathanson, 
2007). The current sheep vaccine is made by formalin inactivation of virus grown in cultured 
cells. At this point it seems unlikely that a human vaccine will be developed.   
2.4.6 Powassan virus 
There is currently no vaccine to protect against infection with Powassan virus, and given the 
extremely small number of cases reported so far, it is somewhat unlikely that a concerted 
vaccine development program will be initiated, in the absence of a significant increase in the 
number of cases. It is possible that some degree of protection against Powassan virus 
infection may be induced by immunization with a vaccine developed against a different 
member of the tick-borne encephalitis group, but this remains speculative at the moment. 
2.4.7 Tick-borne encephalitis virus 
There are currently two vaccines available for prophylactic protection against Tick-borne 
encephalitis virus infections. These vaccines, FSME-Immun (Baxter, Austria) and Encepur 
(Novartis, Germany) are both formalin inactivated whole virus produced in primary 
chicken embryo fibroblasts and are distributed in adult and child formulations. FSME-
Immun is derived from the Austrian Neudorfl strain, while Encepur is derived from the 
German K23 isolate. Both vaccines protect against all three subtypes (European, far-Eastern 
and Siberian) of Tick-borne encephalitis virus and are able to be administered in 
conventional and rapid immunization schedules, although evidence suggests that the 
conventional schedules offer better protection. Both vaccines have undergone considerable 
formulation changes since their original introduction as a consequence of adverse 
immunization events and as both viruses are manufactured using chicken eggs, the 
possibility of hypersensitivity reactions remains. Two further vaccines are available or 
undergoing trials in Russia, the KKhv and IPVE vaccines (Demicheli et al., 2009) but there 
are few if any reports in the English language literature about these formulations. Overall, 
vaccination coverage rates vary dramatically among Tick-borne encephalitis virus endemic 
countries, but where effective vaccination programs are in place as in Austria, a significant 
reduction in Tick-borne encephalitis virus incidence has been observed (Petri et al., 2010). 
However, significant numbers of hospitalizations still occur in endemic countries, despite the 
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availability of vaccines which probably results from the high cost of the vaccines as well as the 
requirement for multiple booster shots to maintain effective protection (Widman et al., 2008). 
Several studies have attempted to use the naturally attenuated Langat virus as the basis of a 
vaccine against Tick-borne encephalitis virus infection. These include large scale (more than 
600,000 individuals) testing in the former USSR of the Yelantsev strain of Langat virus but 
due to an unacceptably high incidence of vaccine associated complications, this approach 
was discontinued. However, a Langat/Dengue 4 chimeric live vaccine which replaces the 
dengue serotype 4 pre-membrane and envelope proteins with the corresponding sequences 
from the Langat virus TP21 strain is currently under development (Pripuzova et al., 2009). 
Other potential live attenuated virus vaccine candidates include a recombinant vaccinia virus 
expressing the tick-borne virus non-structural NS1 protein (Aleshin et al., 2005), a vaccinia 
virus vector carrying the tick-borne encephalitis virus prM/E sequences (Holzer et al., 1999) 
and a self-replicating noninfectious Tick-borne encephalitis virus RNA vaccine based upon the 
Neudoerfl tick-borne encephalitis strain, but containing a large deletion of the sequences 
coding for the capsid protein (Aberle et al., 2005). Potential nucleic acid based (Aberle et al., 
1999; Schmaljohn et al., 1997) and subunit vaccines are also at an early stage of development. 
2.5 Therapeutic agents 
Current treatment for all flavivirus infections is primarily supportive and orientated 
towards alleviating symptoms and there are no specific antivirals marketed to combat 
flaviviral infections. Small scale trials of existing antiviral agents such as ribavirin (Chowers 
et al., 2001) and interferon-α (Solomon et al., 2003) have proved disappointing. There are 
however a large number of compounds currently in the developmental pipeline targeted 
against a number of different processes in the flavivirus life cycle. In addition, therapeutic 
immunoglobulins have shown some promise in animal model systems of West Nile virus 
infection (Ben-Nathan et al., 2003; Oliphant et al., 2005). Current drug compound discovery 
primarily centers on inhibition of virus entry, replication and translation, polyprotein 
processing, virus assembly and cellular host proteins, and while drug development 
primarily focuses on a specific flavivirus, the hope is that a broad spectrum anti-flaviviral 
compound will be discovered. However, the apparent lack of efficacy of ribavirin and 
interferon-α, towards West Nile virus, while these are effective treatments for infections 
with Hepatitis C virus which is a closely related member of the family Flaviviridae (genus 
Hepacivirus), suggests that this may be an unrealistic objective. 
Potential entry inhibitors being evaluated include sulfated glycosaminoglycans, sulfated 
galactomannans and quinazolines which either directly interact with the virus to prevent 
binding to the cell, or interfere with the process of membrane fusion leaving the virus 
trapped at the cell surface. However, the wide sequence diversity of the flavivirus E protein 
suggests that these molecules may have a narrowly defined application. In addition, a 
significant amount of research has suggested that even a single flavivirus may use multiple 
proteins to enter into cells, and that these proteins may differ between different cell types.  
Of even greater concern are the several studies that imply multiple mechanisms of entry for 
some flaviviruses, in addition to endocytosis into clathrin coated pits (Acosta et al., 2009; 
Suksanpaisan et al., 2009), all of which may serve to make the initial host cell: virus 
interaction a less than desirable target.    
Significant attention has focused therefore on the flaviviral proteins with enzymatic activity, 
namely the NS3 and NS5 proteins. The NS3 protein has both protease and helicase activities, 
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while the NS5 protein has methyltransferase and RNA-dependent RNA polymerase 
activities. These proteins, from several different flaviviruses, have been cloned either as a 
complete functional unit of or as a sub-domain expressing a single activity in a number of 
reporter systems, and adapted to high throughput screening assays, allowing the assay of 
many thousands of potential compounds. There are several recent comprehensive reviews 
on the progress of anti-flavivirus drug development (Bollati et al., 2010; Noble et al., 2010; 
Parkinson & Pryde, 2010; Pastorino et al., 2010; Paula et al., 2009).  
3. Conclusions 
The genus flavivirus contains some of the most important vector-borne human pathogens, 
which are widely distributed around the world. Several flaviviruses including some of the 
most important encephalitis causing viruses such as Japanese encephalitis virus, West Nile 
virus and Tick-borne encephalitis virus (both European and Far-Eastern) are considered to 
be emerging infectious diseases  in that they have recently shown an increase in “incidence, 
impact or geographic range” (Jones et al., 2008). Increases in the geographic range of a 
vector borne disease may follow the natural expansion of a host species into new 
geographical locations, or, possibly sudden importation as a result of human activity 
(Pfeffer & Dobler, 2010). However, the sudden and explosive epidemic of chikungunya 
virus (a member of the family Togaviridae, genus Alphavirus) infections in the Indian Ocean 
Islands, India and much of Southeast Asia (Staples et al., 2009) occurred largely as a result of 
the adaptation of the chikungunya virus to transmission by a new host (Aedes albopictus 
instead of Aedes aegypti) and spread internationally by infected humans. This was clearly 
illustrated by the outbreak of chikungunya fever in Italy in 2007, where the disease was 
imported by an infected but presumably pre-symptomatic traveler from India and the virus 
became established in the local Aedes albopictus population. As such, there are several 
potential mechanisms by which vector borne diseases may become established in new areas, 
exposing new populations to the hazards of these diseases.  
Total eradication of the encephalitic flaviviruses seems highly unlikely. While it was 
possible to eliminate the Smallpox virus from nature, this virus was spread through direct 
contact with an infected person or with contaminated fluids or objects, and there is no 
natural reservoir for this virus apart from the human population. With flaviviruses, 
numerous natural host reservoirs exist in the wild, and transovarial transmission of both 
tick-borne and mosquito borne flaviviruses has been documented. Given the inability to 
eradicate these diseases from the wild, efforts to control these diseases and their 
transmission are focused on vector control policies as well as on prevention and cure of the 
disease where human infection does occur. Immunization clearly offers the best solution to 
prevention of these diseases in humans, and as has been seen in the previous section, 
effective vaccines for Japanese encephalitis and tick-borne encephalitis are already available, 
while vaccines for the remaining encephalitis causing diseases (with a few exceptions) are 
generally well advanced. As such research in vaccine development will be essentially focused 
on improvement, both with regards to lowering the incidence of adverse events, as well as 
reducing the cost of the vaccines. With effective vaccines, the critical issue is one of cost. Both 
tick- and mosquito borne encephalitic flaviviruses are common in the developing nations of 
the world, and the main mission will be to make the vaccines affordable for people in resource 
poor countries, and ensure the vaccine is delivered to susceptible population groups. This will 
also entail careful integration of the new vaccines with existing immunization programs. 
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To date, drug development somewhat lags behind vaccine development and there are 
currently no specific anti-flaviviral drugs available, nor any drugs specifically designed to 
combat the consequences of encephalitic manifestations of the disease. However, the advent 
of new technologies has provided a significant boost to drug development programs 
although it remains to be seen whether this will genuinely result in new therapies and 
whether these potential drugs will be broad spectrum or specific to a particular virus 
species. This research however remains of vital importance. While vaccine programs are 
ideal for long-term disease control, vaccine development for flaviviruses takes years or 
decades for a safe, effective and cheap vaccine to be produced. In the event of a massive 
explosion of a previously unregarded flaviviral disease, a broad spectrum anti-flaviviral 
agent may be the only practical solution to reduce high levels of morbidity and mortality.   
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